ABVX

Abivax S.A.

Fundamental data last updated:August 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

FR

Next Earnings Date

09/14/2026

Business Summary

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

 


Analyze ABVX on TradingView

VALUATION

P/E

-27.44

Market Cap ($M USD)

$8.70B

Forward P/E

15.47

PEG

0.06

PRICE TO SALES

0.00

PRICE TO BOOK

17.32

EV / EBITDA

-34.27

5-Year Average P/E

Free Cash Flow Yield

-1.80%

DCF Value

$8.29

Graham Number

N/A

Price to FCF

-55.71

EV to FCF

-52.72

Earnings Yield

-4.26%

FCF Yield

-1.80%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$4.83

Next Year EPS Growth Estimate

$8.57

Next Year Revenue Growth Estimate

$1.62B

Return on Equity (ROE)

-165.19%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.07

Piotroski F-Score

2

Altman Z-Score

31.72

Return on Invested Capital (ROIC)

-48.08%

Current Ratio

8.75

Quick Ratio

8.75

Net Debt to EBITDA

1.94

Interest Coverage

-8.79

Gross Profit margin

0.00%

FCF PER SHARE

$-2.33

REVENUE PER SHARE

$0.00

Analyze ABVX on TradingView

Gainseekers Quantitative Analysis

Summary

ABVX’s valuation paints a perplexing picture. Despite a staggering market cap, the stock traded significantly below its DCF value, suggesting potential mispricing. The Forward P/E of 15.26 indicates optimism for future earnings, contrasting sharply with the negative Earnings Yield, highlighting current profitability struggles. However, the Altman Z-score of 29.20 suggests robust financial health, indicating low bankruptcy risk. This juxtaposition of metrics reveals a company with promising growth prospects but immediate financial challenges.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, ABVX is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The industry's inherent reliance on cutting-edge technology aligns with AI-driven efficiencies. This adaptability could enhance their competitive edge in a rapidly evolving market.

The Bull Case

For the discerning GARP investor, ABVX offers intriguing potential. The Forward PEG ratio of 0.057 suggests the stock is undervalued relative to its growth, while a low Debt/Equity ratio of 0.07 underscores financial prudence. Despite a negative ROIC, the high Altman Z-score and strong Current Ratio indicate a fortress-like balance sheet. These factors, combined with a consensus "Buy" rating, suggest institutional confidence in its future trajectory.

The Bear Case

Yet, the bear case is equally compelling. The Price/Book ratio of 16.11 signals a potentially overvalued stock, especially with zero revenue per share. Negative cash flow metrics, such as a Price to FCF of -51.56, raise red flags about liquidity and operational efficiency. Trading close to its 52-week high, the stock appears technically overextended, posing significant downside risk if growth expectations falter.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$142.17

Institutional Ownership %

1-Year Beta

-0.19

Insider Buying % (6 Mo)

Distance to 52-Week High

12.21%

Distance to 52-Week Low

95.71%

EARNINGS SURPRISE %

24.12%

50-DAY SMA

$118.32

200-DAY SMA

$109.28

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.